Literature DB >> 1331497

Myristate-protein interactions in poliovirus: interactions of VP4 threonine 28 contribute to the structural conformation of assembly intermediates and the stability of assembled virions.

N Moscufo1, M Chow.   

Abstract

The VP4 capsid protein of poliovirus is N-terminally modified with myristic acid. Within the poliovirus structure, a hydrogen bond is observed between the myristate carbonyl and the hydroxyl side chain of threonine 28 of VP4. This interaction is between two fivefold symmetry-related copies of VP4 and is one of several myristoyl-mediated interactions that appears to structurally link the promoters within the pentamer subunit of the virus particle. Site-specific substitutions of the threonine residue were constructed to investigate the biological relevance of these myristate-protein interactions. Replacement of the threonine with glycine or lysine is lethal, generating nonviable viruses. Substitution with serine or valine led to viable viruses, but these mutants displayed anomalies during virus assembly. In addition, both assembled serine- and valine-substituted virion particles showed reduced infectivity and were more sensitive to thermal inactivation and antibody neutralization. Thus the threonine residue provides interactions necessary for efficient assembly of the virus and for virion stability.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331497      PMCID: PMC240287     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  Myristate modification does not function as a membrane association signal during poliovirus capsid assembly.

Authors:  Y M Lee; M Chow
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

2.  In vitro assembly of poliovirus 14 S subunits: identification of the assembly promoting activity of infected cell extracts.

Authors:  B Rombaut; A Foriers; A Boeyé
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

3.  Myristoylation is important at multiple stages in poliovirus assembly.

Authors:  N Moscufo; J Simons; M Chow
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  Lack of myristoylation of poliovirus capsid polypeptide VP0 prevents the formation of virions or results in the assembly of noninfectious virus particles.

Authors:  D Marc; G Masson; M Girard; S van der Werf
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

5.  Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding.

Authors:  C E Fricks; J M Hogle
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

6.  Three-dimensional structure of poliovirus serotype 1 neutralizing determinants.

Authors:  G S Page; A G Mosser; J M Hogle; D J Filman; R R Rueckert; M Chow
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Isolated poliovirus capsid protein VP1 induces a neutralizing response in rats.

Authors:  M Chow; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Poliovirus morphogenesis. I. Identification of 80S dissociable particles and evidence for the artifactual production of procapsids.

Authors:  M E Marongiu; A Pani; M V Corrias; M Sau; P La Colla
Journal:  J Virol       Date:  1981-08       Impact factor: 5.103

View more
  20 in total

1.  Genome delivery and ion channel properties are altered in VP4 mutants of poliovirus.

Authors:  Pranav Danthi; Magdalena Tosteson; Qi-Han Li; Marie Chow
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

2.  Poliovirus 2C region functions during encapsidation of viral RNA.

Authors:  L M Vance; N Moscufo; M Chow; B A Heinz
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity.

Authors:  S Tang; R van Rij; D Silvera; R Andino
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.

Authors:  M K Slifka; R Pagarigan; I Mena; R Feuer; J L Whitton
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Efficient analysis of nonviable poliovirus capsid mutants.

Authors:  J Simons; A Rogove; N Moscufo; C Reynolds; M Chow
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

6.  A mutation in VP4 defines a new step in the late stages of cell entry by poliovirus.

Authors:  N Moscufo; A G Yafal; A Rogove; J Hogle; M Chow
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

7.  A novel N-terminal motif for palmitoylation of G-protein alpha subunits.

Authors:  M Parenti; M A Viganó; C M Newman; G Milligan; A I Magee
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

8.  Quantification of the dynamics of enterovirus 71 infection by experimental-mathematical investigation.

Authors:  Mitsuko Fukuhara; Shingo Iwami; Kei Sato; Yorihiro Nishimura; Hiroyuki Shimizu; Kazuyuki Aihara; Yoshio Koyanagi
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

9.  An infectious cDNA copy of the genome of a non-cardiovirulent coxsackievirus B3 strain: its complete sequence analysis and comparison to the genomes of cardiovirulent coxsackieviruses.

Authors:  N M Chapman; Z Tu; S Tracy; C J Gauntt
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

10.  Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly.

Authors:  P Spearman; J J Wang; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.